Global Health Investment Corporation and EDBI led the $56m Series C financing round in Antheia.

Global Health Investment Corporation, an investment firm, and EDBI, a global investor headquartered in Singapore, led the $56m Series C financing round in Antheia, a biomanufacturing company that produces essential medicine ingredients using advanced biosynthesis, with participation from THOS KG, Federov, Viking Global Investors, Sherpalo Ventures, S-Cubed Capital, In-Q-Tel, and Civilization Ventures. "Our industry-first biosynthetic product offerings are disrupting the market by addressing major supply chain issues and are quickly cementing Antheia's position as a leading industry innovator," Dr. Christina Smolke, Antheia CEO and Co-founder.